April 22, 2024

EMBO | EMBL Symposium: AI and biology

EMBO | EMBL Symposium: AI and biology

Date: 10 – 13 Mar 2026

Location: EMBL Heidelberg and Virtual

Venue: EMBL Advanced Training Centre

Deadline(s):

  • Abstract submission: Closed
  • Registration (On-site): 27 Jan 2026
  • Registration (Virtual): 3 Mar 2026

BioRN members receive a 5 % discount on ticket prices.

Please contact Nicole Hecht (nh(at)biorn.org) for the Discount Code and more Information.


Symposium overview

Artificial intelligence (AI) is transforming virtually all areas of science, and the life sciences are no exception. Following the success of the inaugural 2024 meeting – which brought together an engaged community of researchers both in person and online – the 2026 edition marks the second installment of this growing scientific gathering.

AI-based methods are pushing the limits of what is possible in experimental design, data analysis, simulation, and modelling. The aim of this symposium is to catalyse synergistic interactions between AI researchers in different subfields of biology and biomedicine by exploring shared theoretical approaches, cross-domain experiments, foundation models, and data integration, as well as shared topics in dissemination of tools, agent-based workflows and collaboration with experimental labs. Furthermore, we will look into the future and discuss how the concerted actions of AI and life science communities can enable both fields to exploit the full potential of the ongoing data deluge and find new application areas ripe for disruption by AI.

AI-based analytics is subject to active research in at least three major application areas: sequencing, imaging and structural biology. While all three domains are experiencing very fast growth, the developments are largely happening independently. The aim of our symposium is to convene these communities to discuss topics of mutual interest to make progress, including on the theoretical/methodological side and on the more strategic issues of identifying the next areas of high potential.

Session topics

  • Foundation models for biology
  • Cross-domain, cross-modality learning
  • Explainable AI and mechanistic interpretability
  • From algorithms to biology
  • Generative modeling
  • Emerging topics

The TrustworthyAI4Health Workshop, co-organised by ELSA and EMBL, will take place on 9 March 2026 at EMBL Heidelberg. The workshop focuses on advancing private, fair, and reliable AI models for healthcare, with a strong emphasis on trustworthiness across model design, evaluation, and deployment. Please note that registration for this workshop is handled separately.

register now

Our latest News

discover more
New bioRN Members of 2025

New bioRN Members of 2025

In 2025, the bioRN cluster experienced a strong and dynamic expansion as many new members joined its growing network. This influx of new companies and institutions further strengthened the cluster’s expertise, diversity, and innovative power. The cluster is now pleased to introduce these new members and highlight the diverse capabilities they bring, further reinforcing its […]

ariadne.ai Secures Invest BW Funding to Build “TumorTwin”: The First Digital Twin for Glioblastoma Powered by Morphometric Spatial Multi-Omics

ariadne.ai Secures Invest BW Funding to Build “TumorTwin”: The First Digital Twin for Glioblastoma Powered by Morphometric Spatial Multi-Omics

HEIDELBERG, Germany – January 9, 2026 – ariadne.ai (Germany) GmbH today announced it has been awarded €518,000 in non-dilutive funding from the State of Baden- Württemberg (Invest BW) for its ambitious new project, TumorTwin. The project aims to revolutionize the treatment of Glioblastoma, one of the deadliest and most aggressive brain tumors, by creating a […]

AMGEN acquires Dark Blue Therapeutics, bolstering oncology pipeline

AMGEN acquires Dark Blue Therapeutics, bolstering oncology pipeline

Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million.   The acquisition adds to Amgen’s […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp